中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (6): 410-415.doi: 10.12144/zgmfskin202506410

• 论著 • 上一篇    下一篇

替瑞奇珠单抗治疗32例中重度斑块状银屑病疗效及安全性评价

吴桥芳,包军,孙悦鑫,陶玥   

  1. 南京大学医学院附属鼓楼医院皮肤性病科，江苏南京，210008
  • 出版日期:2025-06-15 发布日期:2025-05-21

Efficacy and safety of tildrakizumab in the treatment of 32 patients with moderate-to-severe plaque psoriasis

WU Qiaofang, BAO Jun, SUN Yuexin, TAO Yue   

  1. Department of Dermatology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China
  • Online:2025-06-15 Published:2025-05-21

PDF (PC)

9

摘要： 目的：评价替瑞奇珠单抗治疗中重度斑块状银屑病的疗效及安全性分析。方法：回顾性分析2024年2～11月在我院就诊的32例接受替瑞奇珠单抗治疗的中重度斑块状银屑病患者的临床资料，所有患者分别于0周、4周给药，之后每12周给药，100 mg/次，皮下注射，于0、4、16周时记录PASI评分和DLQI评分，同时监测患者治疗过程中的疗效和不良反应。结果：32例患者基线、4周、16周PASI评分平均值分别为(15.68±5.87)、(6.48±3.67)和(2.34±5.29)，PASI改善率在16周时达(82.78%±38.39%)，PASI 75/90/100应答率分别为90.63%、71.88%和9.38%。DLQI评分显著降低，16周时DLQI 0/1应答率为37.5%。既往有生物制剂治疗史的患者与无用药史患者疗效无显著差异。32例患者均未出现严重不良事件。结论：替瑞奇珠单抗治疗中重度斑块状银屑病起效迅速，短期疗效显著，无严重不良反应。

关键词: 替瑞奇珠单抗, 中重度斑块状银屑病, 疗效, 安全性

Abstract: Objective: To evaluate the efficacy and safety of tildrakizumab in the treatment of moderate-to-severe plaque psoriasis. Methods: A retrospective analysis was conducted on the clinical data of 32 patients with moderate to severe plaque psoriasis who received treatment with Tildrakizumab in our hospital from February 2024 to November 2024. All patients were administered the drug at week 0 and week 4, followed by once every 12 weeks, with each administration being a 100 mg subcutaneous injection. The PASI and DLQI scores were recorded at weeks 0, 4, and 16. The efficacy and adverse reactions during the treatment process were also monitored. Results: The mean PASI scores of 2 patients at baseline, week 4, and week 16 were 15.68 ± 5.87, 6.48 ± 3.67, and 2.34 ± 5.29, respectively. The PASI improvement rate reached 82.78% ± 38.39% at week 16, with PASI 75, 90, and 100 response rates of 90.63%, 71.88%, and 9.38%, respectively. The DLQI scores were significantly reduced, with a DLQI 0/1 response rate of 37.5% at week 16. There was no significant difference in efficacy between patients with a history of biologic therapy and those without such history. None of the 32 patients experienced serious adverse events. Conclusion: Tildrakizumab has a rapid onset of action in the treatment of moderate-to-severe plaque psoriasis and significant short-term efficacy, with no serious adverse reactions.

Key words: tildrakizumab, moderate-to-severe plaque psoriasis, efficacy, safety